Kumon H, Tomochika K, Matunaga T: A sandwich cup method for the penetration assay of antimicrobial agents through Pseudomonas exopolysaccharides. Microbiol Immunol 1994, 38:615–619.PubMedCrossRef 22. Lewis K: Persister cells: molecular mechanisms related to
antibiotic tolerance. Antibiotic resistance. Handb Exp Pharmacol 2011, 211:121–133.CrossRef 23. Hendricks APA, Budzik JM, So-Young O, Schneedind O: Architects at the bacterial surface – sortases and the assembly of pili with isopeptide bonds. Nat Rev Microbiol 2011, 9:166–176.CrossRef SB-715992 clinical trial 24. Frossard M, Joukhadar C, Erovic BM, Dittrich P, Mrass PE, Van Houte M, Burgmann H, Georgopoulos A, Muller M: Distribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissues. Antimicrob Agents Chemother 2000, 44:2728–2732.PubMedCentralPubMedCrossRef 25. Sun F, Liang H, Kong X, XIe S, Cho H, Deng X, Ji Q, Zhang H, Alvarex S, Hicks LM, Bae T, Luo C, Jiang H, He C: Quorum-sensing agr mediates bacterial oxidation response via an intramolecular disulfide redox switch in the response regulator AgrA. Proc Natl Acad Sci U S A 2012, 109:9095–9100.PubMedCentralPubMedCrossRef 26. Fujimura S, Sato T, Kikuchi T, Zaini J, Gomi K, Watanabe A: Efficacy of clarithromycin plus vancomycin in mice with implant-related
infection caused by biofilm-forming Staphylococcus aureus . J Orthop Sci 2009, 14:658–661.PubMedCrossRef 27. Kahan FM, Kahan JS, Cassidy PJ, Kropp H: The mechanism of action of fosfomycin phosphonomycin). http://www.selleck.co.jp/products/Fludarabine(Fludara).html Ann N Y Acad Sci 1974, 235:364–386.PubMedCrossRef 28. SN-38 in vivo Kikuchi K, Totsuka K, Shimizu K, Ishii T, Yoshida T, Orikasa Y: Effects of combination of benzylpenicillin and fosfomycin on penicillin-resistant Streptococcus pnemoniae . Microb Drug
Resist 1995, 1:185–189.PubMedCrossRef 29. Apisarnthanarak A, Mundy LM: Successful treatment of disseminated methicillin-resistant Staphylococcus aureus with fosfomycin, cefoperzone/sulbactam and selleck screening library rifampin followed by fusidic acid and rifampin. Int J Infect Dis 2007, 11:283–284.PubMedCrossRef 30. Kono K, Takeda S, Tatara I, Arakawa K, Tanaka H, Miyake S, Minamikawa H, Hoshino H, Sato M, Hattori F: Combined therapy with arbekacin and fosfomycin for methicillin-resistant Staphylococcus aureus infections. Jpn J Antibiot 1994, 47:798–803.PubMed 31. Reeves DS: Fosfomycin trometamol. J Antimicrob Chemother 1994, 34:853–858.PubMedCrossRef 32. Hall-Stoodley L, Costerton JW, Stoodley P: Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol 2004, 2:95–108.PubMedCrossRef 33. Garrigós C, Murilloa O, Lora-Tamayoa J, Verdaguer R, Tubau F, Cabellos C, Cabo J, Ariza J: Fosfomycin-daptomycin and other fosfomycin combinations as alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2013, 57:606–610.PubMedCentralPubMedCrossRef 34.